Skip to content

   Pharma Publications

Neuropsychopharmacology
  • Assisting schizophrenia diagnosis using clinical electroencephalography and interpretable graph neural networks: a real-world and cross-site study
    Published on 2023-07-25
    2 years ago
  • The orexin neurotransmitter system as a target for medication development for opioid use disorder
    Published on 2023-07-25
    2 years ago
  • Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence
    Published on 2023-07-25
    2 years ago
  • Correction to: Pathways link environmental and genetic factors with structural brain networks and psychopathology in youth
    Published on 2023-07-25
    2 years ago
  • Puerarin attenuates valproate-induced features of ASD in male mice via regulating Slc7a11-dependent ferroptosis
    Published on 2023-07-25
    2 years ago
  • Bayesian dynamical system analysis of the effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a randomized trial
    Published on 2023-07-25
    2 years ago
  • Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipient
    Published on 2023-07-24
    2 years ago
« Previous 1 … 70 71 72 73 74 … 143 Next »
Journal of Psychopharmacology
  • Selective attention to emotional stimuli and emotion recognition in patients with major depression: The role of mineralocorticoid and glutamatergic NMDA receptors
    Published on 2021-04-28
    4 years ago
  • Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice
    Published on 2021-04-28
    4 years ago
  • Easier patient access to medical cannabis carries risks as well as benefits
    Published on 2021-04-28
    4 years ago
  • Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement
    Published on 2021-04-28
    4 years ago
  • Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia
    Published on 2021-04-28
    4 years ago
  • Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?
    Published on 2021-04-28
    4 years ago
  • Antidepressant action of transcranial direct current stimulation in olfactory bulbectomised adolescent rats
    Published on 2021-04-28
    4 years ago
« Previous 1 … 70 71 72 73 74 … 124 Next »
European Neuropsychopharmacology
  • A review and meta-analysis of gene expression profiles in suicide
    Published on 2021-12-17
    4 years ago
  • Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls
    Published on 2021-12-17
    4 years ago
  • COVID-19 and Behavioral Addictions: Worrying consequences?
    Published on 2021-12-17
    4 years ago
  • Null effect of vortioxetine augmentation with celecoxib should not be generalized to other antidepressants – Author’s reply
    Published on 2021-12-06
    4 years ago
  • Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression
    Published on 2021-11-28
    4 years ago
  • A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
    Published on 2021-11-27
    4 years ago
  • Emotional cognition in depression: Is it relevant for Clinical practice?
    Published on 2021-11-26
    4 years ago
« Previous 1 … 70 71 72 73 74 … 144 Next »

   Pharma Pub